Announcing the Panel Expansion of Afirma Xpression Atlas     LEARN MORE keyboard_arrow_right
MENU

Meta-review Finds That RAS PPV Is Lower Than Previously Reported


Dr. Mark Lupo presented a systematic review of the positive predictive value of RAS mutations at the 25th Annual Meeting of the American Association of Clinical Endocrinologists.



Methods: The literature review in PubMed was conducted through 12/1/2015. Studies were included that reported RAS mutational status and surgical follow-up for cytologically indeterminate nodules. Meta-analyses were constructed calculating the sensitivity, specificity, PPV, and NPV of RAS mutations in cytologically indeterminate nodules.

Results: In the review of 19 studies, RAS was found to have a PPV of 67.7%, in contrast to the 80% that had been quoted recently in the literature. Further analysis revealed that the PPV in the 15 un-blinded studies was 68% compared to the 60% in the 4 studies with blinded pathology review. Furthermore, there was a statistically significant difference in the reported RAS PPV between studies performed at UPMC compared to non-UPMC studies (84% vs 51.5%, p During the presentation, Dr. Lupo presented his own practice’s experience with 18 RAS positive patients from the past 4 years. 15 cytologically indeterminate, RAS positive nodules underwent surgical resection, and 10 (67%) were histologically benign (PPV = 33%).





Summary: “Physicians should be cautious that pathologists are more likely to label a nodule as malignant when they know a RAS mutation is present. This bias may result in cancer over-diagnosis and over-treatment.”

“RAS alone as a mutation in a [thyroid] nodule probably does not have the positive predictive value we thought, and even if they’re cancerous those nodules tend to be fairly indolent”

“We have to take the clinical information together to make the [treatment] decision. RAS alone doesn’t tell the whole story.”

 

Visit http://am.aace.com/sites/all/files/AbstractBook-2016_ALL.pdf (page 286) to read the 2016 AACE abstract

Visit http://www.medscape.com/viewarticle/864088#vp_1 to read the Medscape Medical News article reporting on the AACE 2016 oral presentation

1. Nikiforov YE, et al. JCEM 2009. 2. Ohori PN, et al. Cancer Cytopathology 2010. 3. Nikiforov YE, et al. JCEM 2011. 4. Gupta N, et al. JCEM 2013. 5. Nikiforov YE, et al. Cancer 2014.
6. Nikiforov YE, et al. Thyroid 2015. 7. Cantara S, et al. JCEM 2010. 8. Rossi M, et al. Thyroid 2014. 9. Eslinger M, et al. Best Practice & Research Clin Endocrinology & Metabolism 2014.
10. Eszlinger M, et al. Thyroid 2015. 11. Moses W, et al. World J Surg 2010. 12. Beaudenon-Huibregtse S, et al. Thyroid 2014. 13. Krane JF, et al. Cancer Cytopathology 2015. 14. Medici M,
et al. BMC Medicine 2015. 15. Yoon et al. Medicine 2015. 16. Hwang et al. BioMed Res Intl 2015. 17. Liu et al. Exper and Molec Path 2015. 18. Gill et al. J Oto – Head and Neck Surg 2015. 19. Danilovic et al. Euro J Endo 2015.

 






Contact us today
Monday to Friday, 5:30 AM – 5:00 PM (PST)
Phone: 1.888.923.4762
International: +1.650.243.6335
Fax: 650.243.6388
support@veracyte.com